The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...

Teva Pharmaceutical Industries sues CMS over Medicare drug pricing negotiations policy, claiming agency has unchecked ...

The Centers for Medicare & Medicaid Services Jan. 17 announced a record 24.2 million consumers selected health coverage ...

CMS didn't wait for President-elect Donald Trump to take office before issuing its second list of drugs to be negotiated ...

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing ...

As government scrutiny and enforcement targeting the Medicare Advantage (Medicare Part C) program continued in 2024, the ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

MedRhythms announced that it received a final pricing determination from CMS for its InTandem rehabilitation system.

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...